First-in-class and discovered in India

被引：0

|

作者：

机构：

来源：

Nature Biotechnology | 2021年 / 39卷 / 4期

关键词：

D O I：

10.1038/s41587-021-00906-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：399 / 399

相关论文

共 50 条

[21] FDA approves first-in-class AKT inhibitor
Asher Mullard
Nature Reviews Drug Discovery, 2024, 23 : 9 - 9
[22] FDA approves first-in-class osteoporosis drug
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (06) : 411 - 411
[23] First-in-Class Antimitotic Device Approved for Glioblastoma
不详
ONCOLOGY-NEW YORK, 2011, 25 (06): : 546 - 546
[24] FIRST-IN-CLASS DRUGS IN HTA: BLUNDER OR BLISS?
Politopoulou, K.
Mills, M.
Kanavos, P.
VALUE IN HEALTH, 2023, 26 (12) : S369 - S369
[25] The discovery of first-in-class drugs: origins and evolution
Eder, Joerg
Sedrani, Richard
Wiesmann, Christian
NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (08) : 577 - 587
[26] First-in-class approval rate stays steady
不详
NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (09) : 654 - 654
[27] Perspectives on the development of first-in-class protein degraders
Rambacher, Kalyn M.
Calabrese, Matthew F.
Yamaguchi, Masaya
FUTURE MEDICINAL CHEMISTRY, 2021, 13 (14) : 1203 - 1226
[28] FDA approves first-in-class SYK inhibitor
Asher Mullard
Nature Reviews Drug Discovery, 2018, 17 : 385 - 385
[29] Romosozumab: A first-in-class scierostin inhibitor for osteoprosis
Prather, Caitlin
Adams, Erin
Zentgraf, Whitney
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (23) : 1949 - 1956
[30] First-in-class approval rate stays steady
Nature Reviews Drug Discovery, 2013, 12 : 653 - 653

← 1 2 3 4 5 →